Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis
NCT ID: NCT02505113
Last Updated: 2015-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Polymorphism and Retinopathy of Prematurity: Correlation of Clinical Presentations and Severity
NCT05132257
A Long-term Study for the Outcome of Pompe Disease
NCT02399748
Muscle Response to Enzyme Replacement Therapy in Pompe Disease
NCT00713453
Genomic Study of Congenital Malformation
NCT01250613
Growth Factors and Hepatic Progenitor Cells in Acute Liver Failure
NCT01312220
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CTPV without Montelukast
Patients with CTPV do not receive the treatment of Montelukast.
No interventions assigned to this group
CTPV treated with Montelukast
Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
Montelukast
Montelukast (10mg, q.d., p.o.)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Montelukast
Montelukast (10mg, q.d., p.o.)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Year
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zaibo Jiang
Department of Radiology, The Third Affiliated Hospital, Sun Yat-Sen University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zaibo Jiang, MD
Role: STUDY_CHAIR
Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Radiology
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTPVDORNO3HSYSU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.